Akebia Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AKBA Nasdaq 2834 www.akebia.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Akebia Therapeutics, Inc.

Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook - Jan 12th, 2026 6:00 am
Akebia announces first patient dosed in Phase 2 trial of praliciguat - Jan 7th, 2026 6:22 am
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS) - Jan 6th, 2026 6:00 am
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 5th, 2026 2:05 pm
Akebia Therapeutics Expands Portfolio Beyond Anemia with New Rare Kidney Disease Pipeline Centered on AKB-097 and Praliciguat - Dec 28th, 2025 10:46 am
Analysts Are Optimistic We'll See A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Dec 11th, 2025 4:14 am
This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here? - Dec 2nd, 2025 9:28 am
Top Midday Gainers - Dec 1st, 2025 11:32 am
Akebia Therapeutics Sets Rare Kidney Drug Plan After Q32 Bio Deal - Dec 1st, 2025 6:40 am
Q32 Bio Sells Complement Inhibitor ADX-097 - Dec 1st, 2025 5:00 am
Akebia Announces Establishment of Rare Kidney Disease Pipeline - Dec 1st, 2025 5:00 am
Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference - Nov 24th, 2025 6:00 am
Renal Anemia Market Research Report 2025-2035, Competitive Analysis of Amgen, Sandoz, Pfizer, GlaxoSmithKline, Akebia Therapeutics, and Astellas Pharma - Nov 18th, 2025 8:37 am
Why Is Akebia (AKBA) Up After Strong Vafseo Data and Surging Q3 2025 Revenue? - Nov 14th, 2025 12:14 am
Implied Volatility Surging for Akebia Therapeutics Stock Options - Nov 13th, 2025 9:01 am
Akebia Therapeutics (AKBA): Valuation Insights Following Q3 Profit Surge and Positive Vafseo Clinical Update - Nov 12th, 2025 6:11 am
Theravance's Q3 Earnings Surpass Estimates, Revenues Match - Nov 11th, 2025 8:10 am
Akebia Therapeutics (AKBA) Loses 39.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Nov 11th, 2025 7:35 am
Akebia Therapeutics Inc (AKBA) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... - Nov 10th, 2025 12:01 pm
Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - Nov 10th, 2025 5:00 am